Key facts
- BostonGene’s last known valuation is $1.5B.
- It has raised $320.0M; the latest was Later Stage VC ($120.0M) in Dec 2024.
- Notable investors include Japan Industrial Partners, Impact Investment Capital, NEC (Japan).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for BostonGene
- ·The full record, as it builds
Funding rounds
No funding rounds for BostonGene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BostonGene
Developer of a biomedical software designed for advanced patient analysis and personalized therapy. The company's software offers an artificial intelligence-powered molecular genetic and immune profiling platform to decode cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets, and recommend effective treatments, enabling clinicians to get precise, clinically validated insights that drive precision medicine and advance oncology research.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2015
- Employees
- 300
- Website
- bostongene.com/
- Ownership
- Privately Held (backing)
BostonGene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BostonGene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BostonGene in its N-PORT filings yet. We sweep new filings monthly.